Background
Refractory/relapsed T‐cell acute lymphoblastic leukemia (R/R T‐ALL) is a hematological malignancy with a poor prognosis. The current treatment strategy has not benefited most patients, and the treatment methods are still being explored.
Case presentation
An 8‐year‐old boy with R/R T‐ALL achieved CR after multiple chemotherapies, followed by the first allo‐HSCT. Unfortunately, 1 year and 3 months later, he relapsed. After recurrence, the patient underwent multiple chemotherapies, but the NOTCH1 gene and MRD were still positive. FCM and immunohistochemistry revealed abnormally high expression of CD7, so we considered bridging the second allo‐HSCT after CD7 CAR T‐cells treatment. The patient has low toxic and side effects and is still in CR, findings from this case report have more important therapeutic significance for R/R T‐ALL.
Conclusion
In conclusion, CD7 CAR T‐cells bridging to allo‐HSCT is a safe and effective approach for R/R T‐ALL, resulting in durable CR and longer survival.